Skip to main content
PMC home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2008 Jul;5(3):458–469. doi: 10.1016/j.nurt.2008.05.008

5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease

Neil Upton 1,✉, Tsu Tshen Chuang 1, Ann J Hunter 1, David J Virley 1
PMCID: PMC5084247  PMID: 18625457

Summary

Alzheimer’s disease (AD) is a devastating neurological condition characterized by a progressive decline in cognitive performance accompanied by behavioral and psychological syndromes, such as depression and psychosis. The neurochemical correlates of these clinical manifestations now appear to involve dysfunctions of multiple neurotransmitter pathways. Because of the extensive serotonergic denervation that has been observed in the AD brain and the important role played by serotonin (5-HT) in both cognition and behavioral control, this neurotransmitter system has become a focus of concerted research efforts to identify new treatments for AD. 5-HT exerts its diverse physiological and pharmacological effects through actions on multiple receptor subtypes. One of the newest members of this family is the 5-HT6 receptor, a subtype localized almost exclusively in the CNS, predominating in brain regions associated with cognition and behavior. With the subsequent development of selective 5-HT6 receptor antagonists, preclinical studies in rodents and primates have elucidated the function of this receptor subtype in more detail. It is increasingly clear that blockade of 5-HT6 receptors leads to an improvement of cognitive performance in a wide variety of learning and memory paradigms and also results in anxiolytic and antidepressant-like activity. These actions are largely underpinned by enhancements of cholinergic, glutamatergic, noradrenergic, and dopaminergic neurotransmission, together with learning-associated neuronal remodeling. A preliminary report that the cognitive enhancing properties of a 5-HT6 receptor antagonist (namely, SB-742457) extends into AD sufferers further highlights the therapeutic promise of this mechanistic approach.

Key Words: 5-HT6 receptor antagonists, Alzheimer’s disease, cognition, learning, memory, behavioral symptoms, glutamate, dopamine, acetylcholine, norepinephrine, synaptic plasticity, SB-742457, neural cell adhesion molecule

References

  • 1.Brookmeyer R, Johnson E, Zeigler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dement. 2007;3:186–191. doi: 10.1016/j.jalz.2007.04.381. [DOI] [PubMed] [Google Scholar]
  • 2.Terry AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306:821–827. doi: 10.1124/jpet.102.041616. [DOI] [PubMed] [Google Scholar]
  • 3.Courtney C, Farrell D, Gray R, et al. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105–2115. doi: 10.1016/S0140-6736(04)16499-4. [DOI] [PubMed] [Google Scholar]
  • 4.Ramirez MJ, Aisa B, Garcia-Alloza M, Gil-Bea FJ, Marcos B. Involvement of the serotonergic system in cognitive and behavioral symptoms of Alzheimer’s disease. Curr Psychiatry Rev. 2005;1:337–343. doi: 10.2174/157340005774575073. [DOI] [Google Scholar]
  • 5.Chuang ATT, Foley A, Pugh PL, et al. 5-HT6 receptor antagonist SB-742457 as a novel cognitive enhancing agent for Alzheimer’s disease. Alzheimers Dement. 2006;2:S631–S632. doi: 10.1016/j.jalz.2006.05.2128. [DOI] [Google Scholar]
  • 6.Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993;43:320–327. [PubMed] [Google Scholar]
  • 7.Ruat M, Traiffort E, Arrang J-M, et al. A novel rat serotonin (5-HT6) receptor: molecular cloning, localization, and stimulation of cAMP accumulation. Biochem Biophys Res Commun. 1993;193:268–276. doi: 10.1006/bbrc.1993.1619. [DOI] [PubMed] [Google Scholar]
  • 8.Roberts JC, Reavill C, East S, et al. The distribution of 5-HT6 receptors in rat brain: an autoradiographic radioligand binding study using the radiolabelled 5-HT6 receptor antagonist [6I]SB-258585. Brain Res. 2002;934:49–57. doi: 10.1016/S0006-8993(02)02360-0. [DOI] [PubMed] [Google Scholar]
  • 9.Gérard C, el Mestikawy S, Lebrand C, et al. Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse. 1996;23:164–173. doi: 10.1002/(SICI)1098-2396(199607)23:3<164::AID-SYN5>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  • 10.Hamon M, Doucet E, Lefèvre K, et al. Antibodies and antisense oligonucleotides for probing the distribution and putative functions of central 5-HT6 receptors. Neuropsychopharmacology. 1999;21(Suppl 2):68S–76S. doi: 10.1016/S0893-133X(99)00044-5. [DOI] [PubMed] [Google Scholar]
  • 11.Woolley ML, Marsden CA, Fone KCF. 5-HT6 receptors. Curr Drug Targets CNS Neurol Disord. 2004;3:59–79. doi: 10.2174/1568007043482561. [DOI] [PubMed] [Google Scholar]
  • 12.Hirst WD, Abrahamsen B, Blaney FE, et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol. 2003;64:1295–1308. doi: 10.1124/mol.64.6.1295. [DOI] [PubMed] [Google Scholar]
  • 13.Kohen R, Metcalf MA, Khan N, et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem. 1996;66:47–56. doi: 10.1046/j.1471-4159.1996.66010047.x. [DOI] [PubMed] [Google Scholar]
  • 14.Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther. 2005;108:320–333. doi: 10.1016/j.pharmthera.2005.05.001. [DOI] [PubMed] [Google Scholar]
  • 15.Roth BL, Craigo SC, Choudray MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994;268:1403–1410. [PubMed] [Google Scholar]
  • 16.Sleight AJ, Boess FG, Bös M, Levet-Trafit B, Riemer C, Bourson A. Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors. Br J Pharmacol. 1998;124:556–562. doi: 10.1038/sj.bjp.0701851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Bromidge SM, Brown AM, Clarke SE, et al. 5-Chloro-N-(4-methoxy-3-piperazin-l-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): a potent, selective and orally bioavailable 5-HT6 receptor antagonist. J Med Chem. 1999;42:202–205. doi: 10.1021/jm980532e. [DOI] [PubMed] [Google Scholar]
  • 18.Routledge C, Bromidge SM, Moss SF, et al. Characterization of SB-271046: a potent, selective, orally active 5-HT6 receptor antagonist. Br J Pharmacol. 2000;130:1606–1612. doi: 10.1038/sj.bjp.0703457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hirst WD, Stean TO, Rogers DC, et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol. 2006;553:109–119. doi: 10.1016/j.ejphar.2006.09.049. [DOI] [PubMed] [Google Scholar]
  • 20.Bonhaus DW, Martin R, Brothers J, et al. Ro4368554, a high affinity, selective, CNS penetrating 5-HT6 receptor antagonist. Soc Neurosci Abstr 2002;884.5 (abstract).
  • 21.Schreiber R, Vivian J, Hedley L, et al. Effects of the novel 5-HT6 receptor antagonist Ro4368554 in rat models for cognition and sensorimotor gating. Eur Neuropsychopharmacol. 2007;17:277–288. doi: 10.1016/j.euroneuro.2006.06.009. [DOI] [PubMed] [Google Scholar]
  • 22.Schechter LE, Smith DL, Zhang GM, et al. Pharmacological profile of a novel and selective 5-HT6 receptor agonist. Fundam Clin Pharmacol. 2004;18(Suppl 1):135–151. [Google Scholar]
  • 23.Schechter LE, Lin Q, Smith DL, et al. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology. 2008;33:1323–1335. doi: 10.1038/sj.npp.1301503. [DOI] [PubMed] [Google Scholar]
  • 24.Loiseau F, Dekeyne A, Millan MJ. Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. Psychopharmacology (Berl) 2008;196:93–104. doi: 10.1007/s00213-007-0934-5. [DOI] [PubMed] [Google Scholar]
  • 25.Bourson A, Borroni E, Austin RH, Monsma FJ, Sleight AJ. Determination of the role of the 5-HT6 receptor in the rat brain: a study using antisense oligonucleotides. J Pharmacol Exp Ther. 1995;274:173–180. [PubMed] [Google Scholar]
  • 26.Bentley JC, Bourson A, Boess FG, et al. Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats. Br J Pharmacol. 1999;126:1537–1542. doi: 10.1038/sj.bjp.0702445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137–147. doi: 10.1136/jnnp.66.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22:273–280. doi: 10.1016/S0166-2236(98)01361-7. [DOI] [PubMed] [Google Scholar]
  • 29.Bentley JC, Sleight AJ, Marsden CA, Fone KCF. 5-HT6 antisense oligonucleotide i.c.v. affects rat performance in the water maze and feeding. J Psychopharmacol. 1997;11(3 Suppl):A64–A64. [Google Scholar]
  • 30.Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC. A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology. 2001;41:210–219. doi: 10.1016/S0028-3908(01)00056-9. [DOI] [PubMed] [Google Scholar]
  • 31.Rogers DC, Hagan JJ. 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology (Berl) 2001;158:114–119. doi: 10.1007/s002130100840. [DOI] [PubMed] [Google Scholar]
  • 32.Russell MGN, Dias R. Memories are made of this (perhaps): a review of serotonin 5-HT6 receptor ligands and their biological functions. Curr Top Med Chem. 2002;2:643–654. doi: 10.2174/1568026023393877. [DOI] [PubMed] [Google Scholar]
  • 33.Lindner MD, Hodges DB, Hogan JB, et al. An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning. J Pharmacol Exp Ther. 2003;307:682–691. doi: 10.1124/jpet.103.056002. [DOI] [PubMed] [Google Scholar]
  • 34.Bussey TJ, Muir JL, Aggleton JP. Functionally dissociating aspects of event memory: the effects of combined perirhinal and postrhinal cortex lesions on object and place memory in the rat. J Neurosci. 1999;19:495–502. doi: 10.1523/JNEUROSCI.19-01-00495.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.King MV, Sleight AJ, Woolley ML, Topham IA, Marsden CA, Fone KC. 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation: an effect sensitive to NMDA receptor antagonism. Neuropharmacology. 2004;47:195–204. doi: 10.1016/j.neuropharm.2004.03.012. [DOI] [PubMed] [Google Scholar]
  • 36.Callahan PM, Ilch CP, Rowe WB, Tehim A. Characterization of the selective 5-HT6 receptor antagonist SB-271046 in behavioral models of cognition. Soc Neurosci Abstr 2004;776.19 (abstract).
  • 37.Woolley ML, Marsden CA, Sleight AJ, Fone KC. Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790. Psychopharmacology (Berl) 2003;170:358–367. doi: 10.1007/s00213-003-1552-5. [DOI] [PubMed] [Google Scholar]
  • 38.Lieben CK, Blokland A, Sik A, Sung E, van Nieuwenhuizen P, Schreiber R. The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology. 2005;30:2169–2179. doi: 10.1038/sj.npp.1300777. [DOI] [PubMed] [Google Scholar]
  • 39.Nirogi RV, Vishwakarma SL, Abraham R, Jayarajan P, Goyal RK, Shirsath VS. SUVN-507 reverses scopolamine induced amnesia in Morris water maze and novel object recognition task. Soc Neurosci Abstr 2006;162.12 (abstract).
  • 40.Foley AG, Murphy KJ, Hirst WD, et al. The 5-HT6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology. 2004;29:93–100. doi: 10.1038/sj.npp.1300332. [DOI] [PubMed] [Google Scholar]
  • 41.Szczepanski KV, Vivian JA, Dorsch K, et al. Procognitive effects of the 5-HT6 receptor antagonist Ro4368554 in rats. Soc Neurosci Abstr 2002;290.2 (abstract).
  • 42.Perez-García G, Meneses A. Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task. Pharmacol Biochem Behav 5;81:673–682. [DOI] [PubMed]
  • 43.Hatcher PD, Brown VJ, Tait DS, et al. 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology (Berl) 2005;181:253–259. doi: 10.1007/s00213-005-2261-z. [DOI] [PubMed] [Google Scholar]
  • 44.Wesolowska A, Nikiforuk A. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology. 2007;52:1274–1283. doi: 10.1016/j.neuropharm.2007.01.007. [DOI] [PubMed] [Google Scholar]
  • 45.Nikiforuk A, Wesolowska A, Popik P. Effect of combined administration of the selective serotonin 6 receptor antagonist SB-399885 and antidepressants in the forced swim test in rats. Soc Neurosci Abstr 2007;709.7 (abstract).
  • 46.Wesolowska A, Nikiforuk A, Stachowicz K. Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats. Behav Pharmacol. 2007;18:439–446. doi: 10.1097/FBP.0b013e3282d28f9c. [DOI] [PubMed] [Google Scholar]
  • 47.Pendharkar VV, Vishwakarma SL, Patel AS, Shirsath VS, Kambhampati SR, Nirogi RVS. Effect of selective 5-HT6 receptor antagonists on food-intake and body weight gain. Soc Neurosci Abstr 2005;533.7 (abstract).
  • 48.Jackson HC, Cheetham SC, Dickinson K, et al. Effects of chronic administration and withdrawal of the novel 5-HT6 ligand, E-6837, in a rat model of dietary-induced obesity. Soc Neurosci Abstr 2006;62.2 (abstract).
  • 49.Svartengren J, Axelsson-Lendin P, Multan U, et al. Characterization of a new selective BVT serotonin 5-HT6 receptor antagonist in animal models for feeding and body weight regulation. Soc Neurosci Abstr 2007;629.11 (abstract).
  • 50.Riemer C, Borroni E, Levet-Trafit B, et al. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem. 2003;46:1273–1276. doi: 10.1021/jm021085c. [DOI] [PubMed] [Google Scholar]
  • 51.Zhang MY, Hughes ZA, Kerns EH, Lin Q, Beyer CE. Development of a liquid chromatography/tandem mass spectrometry method for the quantitation of acetylcholine and related neurotransmitters in brain microdialysis samples. J Pharm Biomed Anal. 2007;44:586–593. doi: 10.1016/j.jpba.2007.02.024. [DOI] [PubMed] [Google Scholar]
  • 52.Dawson LA, Nguyen HQ, Li P. In vivo effects of the 5-HT6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br J Pharmacol. 2000;130:23–26. doi: 10.1038/sj.bjp.0703288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Dawson LA, Nguyen HQ, Li P. The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology. 2001;25:662–668. doi: 10.1016/S0893-133X(01)00265-2. [DOI] [PubMed] [Google Scholar]
  • 54.Francis PT, Sims NR, Procter AW, Bowen DM. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer’s disease: investigative and therapeutic perspectives. J Neurochem. 1993;60:1589–1604. doi: 10.1111/j.1471-4159.1993.tb13381.x. [DOI] [PubMed] [Google Scholar]
  • 55.Palmer AM. Neurochemical studies of Alzheimer’s disease. Neurodegeneration. 1996;5:381–391. doi: 10.1006/neur.1996.0051. [DOI] [PubMed] [Google Scholar]
  • 56.Lacroix LP, Dawson LA, Hagan JJ, Heidbreder CA. 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of mono-amines in the rat medial prefrontal cortex. Synapse. 2004;51:158–164. doi: 10.1002/syn.10288. [DOI] [PubMed] [Google Scholar]
  • 57.Kolb B. Functions of the frontal cortex of the rat: a comparative review. Brain Res. 1984;320:65–98. doi: 10.1016/0165-0173(84)90018-3. [DOI] [PubMed] [Google Scholar]
  • 58.Passetti F, Chudasama Y, Robbins TW. The frontal cortex of the rat and visual attentional performance: dissociable functions of distinct medial prefrontal subregions. Cereb Cortex. 2002;12:1254–1268. doi: 10.1093/cercor/12.12.1254. [DOI] [PubMed] [Google Scholar]
  • 59.Dawson LA, Li P. Effects of 5-HT6 receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat. J Neural Transm. 2003;110:577–590. doi: 10.1007/s00702-003-0812-1. [DOI] [PubMed] [Google Scholar]
  • 60.Marcos B, Gil-Bea FJ, Hirst WD, García-Alloza M, Ramírez MJ. Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur J Neurosci. 2006;24:1299–1306. doi: 10.1111/j.1460-9568.2006.05003.x. [DOI] [PubMed] [Google Scholar]
  • 61.Gerard C, Martres MP, Lefèvre K, et al. Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res. 1997;746:207–219. doi: 10.1016/S0006-8993(96)01224-3. [DOI] [PubMed] [Google Scholar]
  • 62.Persohn E, Schachner M. Immunoelectron microscopic localization of the neural cell adhesion molecules L1 and N-CAM during postnatal development of the mouse cerebellum. J Cell Biol. 1987;105:569–576. doi: 10.1083/jcb.105.1.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Schuster T, Krug M, Stalder M, Hackel N, Gerardy-Schahn R, Schachner M. Immunoelectron microscopic localization of the neural recognition molecules L1, NCAM, and its isoform NCAM180, the NCAM-associated polysialic acid, beta1 integrin and the extracellular matrix molecule tenascin-R in synapses of the adult rat hippocampus. J Neurobiol. 2001;49:142–158. doi: 10.1002/neu.1071. [DOI] [PubMed] [Google Scholar]
  • 64.Doyle E, Nolan PM, Bell R, Regan CM. Intraventricular infusions of anti-neural cell adhesion molecules in a discrete posttraining period impair consolidation of a passive avoidance response in the rat. J Neurochem. 1992;59:1570–1573. doi: 10.1111/j.1471-4159.1992.tb08477.x. [DOI] [PubMed] [Google Scholar]
  • 65.Scholey AB, Rose SP, Zamani MR, Bock E, Schachner M. A role for the neural cell adhesion molecule in a late, consolidating phase of glycoprotein synthesis six hours following passive avoidance training of the young chick. Neuroscience. 1993;55:499–509. doi: 10.1016/0306-4522(93)90519-L. [DOI] [PubMed] [Google Scholar]
  • 66.Lüthl A, Laurent JP, Figurov A, Muller D, Schachner M. Hippocampal long-term potentiation and neural cell adhesion molecules L1 and NCAM. Nature. 1994;372:777–779. doi: 10.1038/372777a0. [DOI] [PubMed] [Google Scholar]
  • 67.Sadoul R, Hirn M, Deagostini-Bazin H, Rougon G, Goridis C. Adult and embryonic mouse neural cell adhesion molecules have different binding properties. Nature. 1983;304:347–349. doi: 10.1038/304347a0. [DOI] [PubMed] [Google Scholar]
  • 68.Moran N, Bock E. Characterization of the kinetics of neural cell adhesion molecule homophilic binding. FEBS Lett. 1988;242:121–124. doi: 10.1016/0014-5793(88)80998-0. [DOI] [PubMed] [Google Scholar]
  • 69.Muller D, Wang C, Skibo G, et al. PSA-NCAM is required for activity-induced synaptic plasticity. Neuron. 1996;7:413–422. doi: 10.1016/S0896-6273(00)80174-9. [DOI] [PubMed] [Google Scholar]
  • 70.Becker CG, Artola A, Gerardy-Schahn R, Becker T, Welzl H, Schachner M. The polysialic acid modification of the neural cell adhesion molecule is involved in spatial learning and hippocampal long-term potentiation. J Neurosci Res. 1996;45:143–152. doi: 10.1002/(SICI)1097-4547(19960715)45:2<143::AID-JNR6>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  • 71.Venero C, Herrero AI, Touyarot K, et al. Hippocampal up-regulation of NCAM expression and polysialylation plays a key role on spatial memory. Eur J Neurosci. 2006;23:1585–1595. doi: 10.1111/j.1460-9568.2006.04663.x. [DOI] [PubMed] [Google Scholar]
  • 72.Diyatev A, Dityateva G, Sytnyk V, et al. Polysialylated neural cell adhesion molecule promotes remodeling and formation of hippocampal synapses. J Neurosci. 2004;24:9372–9382. doi: 10.1523/JNEUROSCI.1702-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Markram K, Gerardy-Schahn R, Sandi C. Selective learning and memory impairments in mice deficient for polysialylated NCAM in adulthood. Neuroscience. 2007;144:788–796. doi: 10.1016/j.neuroscience.2006.10.024. [DOI] [PubMed] [Google Scholar]
  • 74.Seki T, Arai Y. Highly polysialylated neural cell adhesion molecule (NCAM-H) is expressed by newly generated granule cells in the dentate gyrus of the adult rat. J Neurosci. 1993;13:2351–2358. doi: 10.1523/JNEUROSCI.13-06-02351.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Seki T, Arai Y. Different polysialic acid-neural cell adhesion molecule expression patterns in distinct types of mossy fiber boutons in the adult hippocampus. J Comp Neurol. 1999;410:115–125. doi: 10.1002/(SICI)1096-9861(19990719)410:1<115::AID-CNE10>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  • 76.Ní Dhúill CM, Fox GB, Pittock SJ, O’Connell AW, Murphy KJ, Regan CM. Polysialylated neural cell adhesion molecule expression in the dentate gyrus of the human hippocampal formation from infancy to old age. J Neurosci Res. 1999;55:99–106. doi: 10.1002/(SICI)1097-4547(19990101)55:1<99::AID-JNR11>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  • 77.Ge S, Yang CH, Hsu KS, Ming GL, Song H. A critical period for enhanced synaptic plasticity in newly generated neurons of the adult brain. Neuron. 2007;54:559–566. doi: 10.1016/j.neuron.2007.05.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Zhao C, Teng EM, Summers RG, Ming GL, Gage FH. Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J Neurosci. 2006;26:3–11. doi: 10.1523/JNEUROSCI.3648-05.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Kee N, Teixeira CM, Wang AH, Frankland PW. Preferential incorporation of adult-generated granule cells into spatial memory networks in the dentate gyrus. Nat Neurosci. 2007;10:355–362. doi: 10.1038/nn1847. [DOI] [PubMed] [Google Scholar]
  • 80.Kitabatake Y, Sailor KA, Ming GL, Song H. Adult neurogenesis and hippocampal memory function: new cells, more plasticity, new memories? Neurosurg Clin N Am. 2007;18:105–113. doi: 10.1016/j.nec.2006.10.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Senkov O, Sun M, Weinhold B, Gerardy-Schahn R, Schachner M, Dityatev A. Polysialylated neural cell adhesion molecule is involved in induction of long-term potentiation and memory acquisition and consolidation in a fear-conditioning paradigm. J Neurosci. 2006;26:10888–10898. doi: 10.1523/JNEUROSCI.0878-06.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Lopez-Femandez MA, Montaron MF, Varea E, et al. Upregulation of polysialylated neural cell adhesion molecule in the dorsal hippocampus after contextual fear conditioning is involved in long-term memory formation. J Neurosci. 2007;27:4552–4561. doi: 10.1523/JNEUROSCI.0396-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Johnson CN, Roland A, Upton N. New symptomatic strategies in Alzheimer’s disease. Drug Discov Today Ther Strateg. 2004;1:13–20. doi: 10.1016/j.ddstr.2004.08.003. [DOI] [Google Scholar]
  • 84.Foley AG, Hirst WD, Gallagher HS, et al. The 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats. Neuropharmacology. 2008;54:1166–1174. doi: 10.1016/j.neuropharm.2008.03.012. [DOI] [PubMed] [Google Scholar]
  • 85.Yun HM, Kim S, Kim HJ, et al. The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. J Biol Chem. 2007;282:5496–5505. doi: 10.1074/jbc.M606215200. [DOI] [PubMed] [Google Scholar]
  • 86.Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448–6453. doi: 10.1073/pnas.95.11.6448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Chin J, Palop JJ, Puoliväli J, et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer’s disease. J Neurosci. 2005;25:9694–9703. doi: 10.1523/JNEUROSCI.2980-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Lee G, Thangavel R, Sharma VM, et al. Phosphorylation of tau by fyn: implications for Alzheimer’s disease. J Neurosci. 2004;24:2351–2358. doi: 10.1523/JNEUROSCI.4162-03.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Dunah AW, Sirianni AC, Fienberg AA, Bastia E, Schwarzschild MA, Standaert DG. Dopamine D1-dependent trafficking of striatal N-methyl-d-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol. 2004;65:121–129. doi: 10.1124/mol.65.1.121. [DOI] [PubMed] [Google Scholar]
  • 90.Grant SG, O’Dell TJ, Karl KA, Stein PL, Soriano P, Kandel ER. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science. 1992;258:1903–1910. doi: 10.1126/science.1361685. [DOI] [PubMed] [Google Scholar]
  • 91.Miyakawa T, Yagi T, Watanabe S, Niki H. Increased fearfulness of Fyn tyrosine kinase deficient mice. Mol Brain Res. 1994;27:179–182. doi: 10.1016/0169-328X(94)90201-1. [DOI] [PubMed] [Google Scholar]
  • 92.Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry. 2003;18(Suppl 1):S23–S32. doi: 10.1002/gps.938. [DOI] [PubMed] [Google Scholar]
  • 93.Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006;l:CD001190–CD001190. doi: 10.1002/14651858.CD001190.pub2. [DOI] [PubMed] [Google Scholar]
  • 94.Tariot PN, Fallow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil. JAMA. 2004;291:317–324. doi: 10.1001/jama.291.3.317. [DOI] [PubMed] [Google Scholar]
  • 95.Haider JA, Ridley RM. The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology. 2000;39:547–552. doi: 10.1016/S0028-3908(99)00179-3. [DOI] [PubMed] [Google Scholar]
  • 96.Schechter LE, Smith DL, Rosenzweig-Lipson S, et al. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther. 2005;314:1274–1289. doi: 10.1124/jpet.105.086363. [DOI] [PubMed] [Google Scholar]
  • 97.Deisseroth K, Singla S, Toda H, Monje M, Palmer TD, Malenka RC. Excitation-neurogenesis coupling in adult neural stem/progenitor cells. Neuron. 2004;42:535–552. doi: 10.1016/S0896-6273(04)00266-1. [DOI] [PubMed] [Google Scholar]
  • 98.Murphy KJ, O’Connell AW, Regan CM. Repetitive and transient increases in hippocampal neural cell adhesion molecule polysialylation state following multitrial spatial training. J Neurochem. 1996;67:1268–1274. doi: 10.1046/j.1471-4159.1996.67031268.x. [DOI] [PubMed] [Google Scholar]
  • 99.Fox GB, O’Connell AW, Murphy KJ, Regan CM. Memory consolidation induces a transient and time-dependent increase in the frequency of neural cell adhesion molecule polysialylated cells in the adult rat hippocampus. J Neurochem. 1995;65:2796–2799. doi: 10.1046/j.1471-4159.1995.65062796.x. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES